Therapeutic Goods Administration
Low-dose atropine EIKANCE secures first myopia TGA approval
The Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children ...
Tasmanian centre joins race for CRISPR blindness cures
In 2016, at his home RANZCO scientific branch meeting in Tasmania, preeminent ophthalmic genetics expert Professor Alex Hewitt presented on ...
ECPs can offer COVID-19 vaccine incentives, TGA says
Optometry Australia (OA) is urging caution for practices considering offering gifts or discounts to fully vaccinated patients as part of ...
Glaukos announces TGA approval of late-stage glaucoma implant
Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to ...
Prednefrin Forte shortage – TGA approves alternative product
Allergan has secured regulatory approval for an alternative product to address a Prednefrin Forte shortage in Australia. The company confirmed ...
Optometrists back Aussie-developed AI system
Australian optometrists are reporting positive results with a homegrown clinical decision support tool that uses artificial intelligence (AI) to analyse ...
Prednefrin Forte shortage: supplier working towards providing alternative
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn't expected ...
Race to identify inherited retinal disease patients for gene therapies
Australian researchers are using genetic testing to identify as many people as possible with inherited retinal disease (IRD), in preparation ...
TGA approves first pharma option for proliferative diabetic retinopathy
For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have ...